{
    "clinical_study": {
        "@rank": "134377", 
        "arm_group": {
            "arm_group_label": "Peginesatide / Epoetin Alfa", 
            "arm_group_type": "Experimental", 
            "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can\n      be converted to epoetin alfa by using a predefined conversion table while achieving a stable\n      hemoglobin."
        }, 
        "brief_title": "Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                        "title": "Peginesatide"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "41"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "16.6", 
                                            "@value": "63.2"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "21"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "20"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "24"
                                            }
                                        }, 
                                        "sub_title": "Black or African American"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "16"
                                            }
                                        }, 
                                        "sub_title": "White"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Other"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Race/Ethnicity, Customized", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants.\nNo participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                                "title": "Peginesatide"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants.\nNo participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.", 
                                    "title": "Mean Hemoglobin Concentration During the Evaluation Period"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).", 
                        "title": "Mean Hemoglobin Concentration During the Evaluation Period", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "No participant reached the evaluation period, therefore, this endpoint could not be evaluated.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                                "title": "Peginesatide"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "No participant reached the evaluation period, therefore, this endpoint could not be evaluated.", 
                                    "title": "Mean Dose of Epoetin Alfa During the Evaluation Period"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56).", 
                        "title": "Mean Dose of Epoetin Alfa During the Evaluation Period", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                                "title": "Peginesatide"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "34"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.76", 
                                                        "@value": "10.51"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=34)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.81", 
                                                        "@value": "11.09"
                                                    }
                                                }, 
                                                "sub_title": "Week 3 (n=34)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.87", 
                                                        "@value": "10.86"
                                                    }
                                                }, 
                                                "sub_title": "Week 5 (n=29)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.02", 
                                                        "@value": "11.03"
                                                    }
                                                }, 
                                                "sub_title": "Week 7 (n=21)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.84", 
                                                        "@value": "10.59"
                                                    }
                                                }, 
                                                "sub_title": "Week 9 (n=20)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.97", 
                                                        "@value": "10.80"
                                                    }
                                                }, 
                                                "sub_title": "Week 11 (n=19)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.94", 
                                                        "@value": "10.50"
                                                    }
                                                }, 
                                                "sub_title": "Week 13 (n=14)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.82", 
                                                        "@value": "10.70"
                                                    }
                                                }, 
                                                "sub_title": "Week 15 (n=10)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.31", 
                                                        "@value": "10.35"
                                                    }
                                                }, 
                                                "sub_title": "Week 17 (n=10)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.94", 
                                                        "@value": "10.93"
                                                    }
                                                }, 
                                                "sub_title": "Week 19 (n=10)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "#text": "Data only available for one participant", 
                                                        "@group_id": "O1", 
                                                        "@spread": "NA", 
                                                        "@value": "10.10"
                                                    }
                                                }, 
                                                "sub_title": "Week 21 (n=1)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0.63", 
                                                        "@value": "10.55"
                                                    }
                                                }, 
                                                "sub_title": "End of study visit (n=32)"
                                            }
                                        ]
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Hemoglobin Concentration by Visit", 
                                    "units": "g/dL"
                                }
                            ]
                        }, 
                        "population": "Primary analysis set includes all enrolled participants who received at least 1 dose of investigational product. The number of participants with available data at each time point is indicated by \"n\".", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21", 
                        "title": "Hemoglobin Concentration by Visit", 
                        "type": "Secondary"
                    }, 
                    {
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                                "title": "Peginesatide"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "34"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.48", 
                                                        "@value": "5.42"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=30)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "1.32", 
                                                        "@value": "5.04"
                                                    }
                                                }, 
                                                "sub_title": "Week 5 (n=16)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.00", 
                                                        "@value": "4.98"
                                                    }
                                                }, 
                                                "sub_title": "Week 9 (n=15)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "2.53", 
                                                        "@value": "4.00"
                                                    }
                                                }, 
                                                "sub_title": "Week 13 (n=9)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "3.29", 
                                                        "@value": "5.12"
                                                    }
                                                }, 
                                                "sub_title": "Week 17 (n=9)"
                                            }
                                        ]
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Peginesatide Dose by Visit", 
                                    "units": "mg"
                                }
                            ]
                        }, 
                        "population": "Primary analysis set, with available data at each time point (indicated by n)", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Weeks 5, 9, 13, and 17", 
                        "title": "Peginesatide Dose by Visit", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                        "title": "Peginesatide"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Death"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "40", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Sponsor decision"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "41", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "34", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Received Peginesatide"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Transitioned to Epoetin Alfa"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "41", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "First patient was enrolled on 24 October 2012; Last patient was enrolled on 21 February 2013. The study was terminated on 27 March 2013."
            }, 
            "point_of_contact": {
                "name_or_title": "Study Director", 
                "organization": "Amgen Inc.", 
                "phone": "866-572-6436"
            }, 
            "reported_events": {
                "desc": "The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.", 
                        "title": "Peginesatide"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "6", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Oedema"
                                    }
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Headache"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "2", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Hypertension"
                                    }
                                }, 
                                "title": "Vascular disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Ventricular asystole"
                                    }
                                }, 
                                "title": "Cardiac disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Small intestinal obstruction"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "34"
                                        }, 
                                        "sub_title": "Cholelithiasis"
                                    }
                                }, 
                                "title": "Hepatobiliary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "34"
                                            }, 
                                            "sub_title": "Gastroenteritis"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "34"
                                            }, 
                                            "sub_title": "Pneumonia"
                                        }
                                    ]
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "34"
                                            }, 
                                            "sub_title": "Pulmonary embolism"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "34"
                                            }, 
                                            "sub_title": "Pulmonary oedema"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA 16.0"
                }, 
                "time_frame": "From informed consent up to 30 days post treatment, or end of study. Maximum time on study was 6 months."
            }
        }, 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "detailed_description": {
            "textblock": "This is a phase 4, multicenter, single-arm, open-label study designed to evaluate whether\n      patients receiving hemodialysis and treated with peginesatide can be converted to epoetin\n      alfa using a predefined conversion table while achieving stable hemoglobin. The study will\n      be conducted in two phases. Hemodialysis patients treated with epoetin alfa 3 times a week\n      (TIW) will first be converted to peginesatide administered every 4 weeks (Q4W). After 24\n      weeks, these participants will be converted back to epoetin alfa administered TIW for 32\n      weeks.  The primary endpoint will be the mean hemoglobin during the last 8 weeks of the\n      epoetin alfa period."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Receiving hemodialysis 3 times a week\n\n          -  Receiving epoetin alfa IV 3 times a week\n\n          -  Hemoglobin concentration \u2265 9.0 and \u2264 12.0 g/dL within 8 weeks of or during screening\n\n        Key Exclusion Criteria:\n\n          -  Systemic hematologic disease\n\n          -  Changes in Epoetin alfa dose by \u2265 50% within 8 weeks of or during screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "firstreceived_results_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01737879", 
            "org_study_id": "20110209"
        }, 
        "intervention": [
            {
                "arm_group_label": "Peginesatide / Epoetin Alfa", 
                "description": "All participants will receive peginesatide for the first 24 weeks.", 
                "intervention_name": "Peginesatide", 
                "intervention_type": "Drug", 
                "other_name": "Omontys"
            }, 
            {
                "arm_group_label": "Peginesatide / Epoetin Alfa", 
                "description": "All participants converted to epoetin alfa at week 25 for a total of 32 weeks", 
                "intervention_name": "Epoetin alfa", 
                "intervention_type": "Drug", 
                "other_name": "Epogen"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Epoetin Alfa", 
                "Hematinics"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Anemia, Chronic Kidney Disease, End Stage Renal Disease, erythropoiesis-stimulating agents, Hemodialysis, Hemoglobin", 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85004"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tempe", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85284"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Azusa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91702"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bakersfield", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93309"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Granada Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91344"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90057"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lynwood", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90262"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paramount", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90723"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Riverside", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92501"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Whittier", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90603"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06477"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meridian", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83642"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64111"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bayonne", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07002"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amherst", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14221"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yonkers", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10704"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27103"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73116"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orangeburg", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29118"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dyersburg", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38024"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38305"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chesapeake", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23320"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The hemoglobin concentrations during the evaluation period after the conversion to epoetin alfa were to be averaged for each participant and then summarized over all participants.\nNo participant reached the evaluation period, therefore, the primary efficacy endpoint could not be evaluated.", 
            "measure": "Mean Hemoglobin Concentration During the Evaluation Period", 
            "safety_issue": "No", 
            "time_frame": "Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01737879"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "No participant reached the evaluation period, therefore, this endpoint could not be evaluated.", 
                "measure": "Mean Dose of Epoetin Alfa During the Evaluation Period", 
                "safety_issue": "No", 
                "time_frame": "Last 8 weeks of epoetin alfa treatment period period (Weeks 49 to 56)."
            }, 
            {
                "measure": "Hemoglobin Concentration by Visit", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21"
            }, 
            {
                "measure": "Peginesatide Dose by Visit", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Weeks 5, 9, 13, and 17"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted\n    prematurely and will not resume; participants are no longer being treated"
    }
}